首页 > 最新文献

Breast disease最新文献

英文 中文
Cancer associated fibroblasts modulate the cytotoxicity of anti-cancer drugs in breast cancer: An in vitro study. 癌症相关成纤维细胞调节乳腺癌抗癌药物的细胞毒性:体外研究
Pub Date : 2024-01-01 DOI: 10.3233/BD-230011
Dharambir Kashyap, Shalmoli Bhattacharya, Santosh Irinike, Siddhant Khare, Ashim Das, Gurpreet Singh, Amanjit Bal

Background: Tumour microenvironment (TME) contributes to resistance to anti-cancer drugs through multiple mechanisms including secretion of pro-survival factors by cancer associated fibroblasts (CAFs). In this study, we determined the chemotherapy resistance producing potential of CAFs in molecular subtypes of breast cancer.

Methods: The CAFs were isolated from fresh lumpectomy/mastectomy specimens of different molecular subtypes of breast cancer. The CAFs were cultured and secretome was collected from each breast cancer subtype. Breast cancer cell lines MCF-7, SK-BR3, MDA-MB-231, and MDA-MB-468 were treated with different doses of tamoxifen, trastuzumab, cisplatin, and doxorubicin alone respectively and in combination with secretome of CAFs from respective subtypes. MTT assay was done to check cell death after drug treatment. Liquid chromatography-mass spectrometry (LCMS) analysis of CAF secretome was also done.

Results: MTT assay showed that anti-cancer drugs alone had growth inhibitory effect on the cancer cells however, presence of CAF secretome reduced the anti-cancer effect of the drugs. Resistant to drugs in the presence of secretome, was determined by increased cell viability i.e., MCF-7, 51.02% to 63.02%; SK-BR-3, 34.22% to 44.88%; MDA-MB-231, 52.59% to 78.63%; and MDA-MB-468, 48.92% to 55.08%. LCMS analysis of the secretome showed the differential abundance of CAFs secreted proteins across breast cancer subtypes.

Conclusions: The treatment of breast cancer cell lines with anti-cancer drugs in combination with secretome isolated from molecular subtype specific CAFs, reduced the cytotoxic effect of the drugs. In addition, LCMS data also highlighted different composition of secreted proteins from different breast cancer associated fibroblasts. Thus, TME has heterogenous population of CAFs across the breast cancer subtypes and in vitro experiments highlight their contribution to chemotherapy resistance which needs further validation.

背景:肿瘤微环境(TME)通过癌症相关成纤维细胞(CAFs)分泌促生存因子等多种机制导致抗癌药物的耐药性。本研究测定了乳腺癌分子亚型中 CAFs 产生化疗耐药性的潜力:方法:从不同分子亚型乳腺癌的新鲜肿块切除术/乳房切除术标本中分离出 CAFs。培养 CAFs 并收集各亚型乳腺癌的分泌物。乳腺癌细胞系 MCF-7、SK-BR3、MDA-MB-231 和 MDA-MB-468,分别单独使用不同剂量的他莫昔芬、曲妥珠单抗、顺铂和多柔比星,以及与各亚型的 CAFs 分泌物联合使用。MTT 试验用于检测药物治疗后的细胞死亡情况。还对 CAF 分泌组进行了液相色谱-质谱(LCMS)分析:MTT 试验表明,单独使用抗癌药物对癌细胞有生长抑制作用,但 CAF 分泌组的存在降低了药物的抗癌效果。在有分泌物存在的情况下,细胞存活率的增加决定了对药物的耐药性,即 MCF-7,51.02% 至 63.02%;SK-BR-3,34.22% 至 44.88%;MDA-MB-231,52.59% 至 78.63%;MDA-MB-468,48.92% 至 55.08%。分泌组的 LCMS 分析表明,不同亚型乳腺癌的 CAFs 分泌蛋白丰度不同:结论:使用抗癌药物治疗乳腺癌细胞系时,结合使用从分子亚型特异性 CAFs 中分离出的分泌物组,可降低药物的细胞毒性作用。此外,LCMS 数据还突显了不同乳腺癌相关成纤维细胞分泌蛋白的不同组成。因此,TME 在乳腺癌亚型中具有异质性的 CAFs 群体,体外实验强调了它们对化疗耐药性的贡献,这需要进一步验证。
{"title":"Cancer associated fibroblasts modulate the cytotoxicity of anti-cancer drugs in breast cancer: An in vitro study.","authors":"Dharambir Kashyap, Shalmoli Bhattacharya, Santosh Irinike, Siddhant Khare, Ashim Das, Gurpreet Singh, Amanjit Bal","doi":"10.3233/BD-230011","DOIUrl":"10.3233/BD-230011","url":null,"abstract":"<p><strong>Background: </strong>Tumour microenvironment (TME) contributes to resistance to anti-cancer drugs through multiple mechanisms including secretion of pro-survival factors by cancer associated fibroblasts (CAFs). In this study, we determined the chemotherapy resistance producing potential of CAFs in molecular subtypes of breast cancer.</p><p><strong>Methods: </strong>The CAFs were isolated from fresh lumpectomy/mastectomy specimens of different molecular subtypes of breast cancer. The CAFs were cultured and secretome was collected from each breast cancer subtype. Breast cancer cell lines MCF-7, SK-BR3, MDA-MB-231, and MDA-MB-468 were treated with different doses of tamoxifen, trastuzumab, cisplatin, and doxorubicin alone respectively and in combination with secretome of CAFs from respective subtypes. MTT assay was done to check cell death after drug treatment. Liquid chromatography-mass spectrometry (LCMS) analysis of CAF secretome was also done.</p><p><strong>Results: </strong>MTT assay showed that anti-cancer drugs alone had growth inhibitory effect on the cancer cells however, presence of CAF secretome reduced the anti-cancer effect of the drugs. Resistant to drugs in the presence of secretome, was determined by increased cell viability i.e., MCF-7, 51.02% to 63.02%; SK-BR-3, 34.22% to 44.88%; MDA-MB-231, 52.59% to 78.63%; and MDA-MB-468, 48.92% to 55.08%. LCMS analysis of the secretome showed the differential abundance of CAFs secreted proteins across breast cancer subtypes.</p><p><strong>Conclusions: </strong>The treatment of breast cancer cell lines with anti-cancer drugs in combination with secretome isolated from molecular subtype specific CAFs, reduced the cytotoxic effect of the drugs. In addition, LCMS data also highlighted different composition of secreted proteins from different breast cancer associated fibroblasts. Thus, TME has heterogenous population of CAFs across the breast cancer subtypes and in vitro experiments highlight their contribution to chemotherapy resistance which needs further validation.</p>","PeriodicalId":9224,"journal":{"name":"Breast disease","volume":"43 1","pages":"25-36"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10977379/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140189412","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A novel PIK3CA hot-spot mutation in breast cancer patients detected by HRM-COLD-PCR analysis. 通过HRM-COLD-PCR分析发现乳腺癌患者中的一种新型PIK3CA热点突变。
Pub Date : 2024-01-01 DOI: 10.3233/BD-240005
Saoussen Debouki-Joudi, Wala Ben Kridis, Fatma Trifa, Wajdi Ayadi, Abdelmajid Khabir, Tahia Sellami-Boudawara, Jamel Daoud, Afef Khanfir, Raja Mokdad-Gargouri

Background: The PI3K protein is involved in the PI3K/AKT/mTOR pathway. Deregulation of this pathway through PIK3CA mutation is common in various tumors. The aim of this work is to identify hotspot mutation at exons 9 and 20 in Tunisian patients with sporadic or hereditary breast cancer.

Methods: Hotspot mutations in exon 9 and exon 20 of the PIK3CA gene were identified by QPCR-High Resolution Melting followed by COLD-PCR and sequencing in 63 (42 sporadic cases and 21 hereditary cases) tumor tissues collected from Tunisian patient with breast cancer. MCF7, and BT20 breast cancer cell lines harboring the PIK3CA hotspot mutations E545K and H1047R in exon 9 and exon 20 respectively, were used as controls in HRM experiments.

Results: PIK3CA hotspot mutations were detected in 66.7% (28 out of 42) of sporadic BC cases, and in 14.3% (3 out of 21) of hereditary BC. The E545K and the H1048Y were the most prevalent mutations identified in patients with sporadic and hereditary BC, whereas the H1047R hotspot mutation was not found in our patients. Statistical analysis showed that PIK3CA mutation associated with an aggressive behavior in patients with sporadic BC, while it's correlated with age, tumor stage and tumor size in the group patients with hereditary breast cancer.

Conclusions: Our results showed a novel PIK3CA hotspot mutation in Tunisian breast cancer patients detected by HRM-COLD-PCR. Moreover, the absence of PIK3CA hotspot mutation associated with good prognosis.

背景:PI3K 蛋白参与 PI3K/AKT/mTOR 通路。PIK3CA突变导致该通路失调在各种肿瘤中很常见。方法:通过 QPCR-高分辨熔解技术,然后通过 COLD-PCR 和测序技术,对从突尼斯乳腺癌患者中收集的 63 例(42 例散发性病例和 21 例遗传性病例)肿瘤组织中的 PIK3CA 基因第 9 号外显子和第 20 号外显子的热点突变进行鉴定。MCF7和BT20乳腺癌细胞系分别在外显子9和外显子20中携带PIK3CA热点突变E545K和H1047R,它们被用作HRM实验的对照:结果:在66.7%的散发性BC病例(42例中的28例)和14.3%的遗传性BC病例(21例中的3例)中检测到了PIK3CA热点突变。E545K和H1048Y是散发性和遗传性BC患者中最常见的突变,而H1047R热点突变在我们的患者中没有发现。统计分析显示,PIK3CA突变与散发性乳腺癌患者的侵袭行为有关,而与遗传性乳腺癌患者的年龄、肿瘤分期和肿瘤大小有关:我们的研究结果表明,在突尼斯乳腺癌患者中,通过 HRM-COLD-PCR 检测到了一种新型 PIK3CA 热点突变。此外,PIK3CA热点突变的缺失与良好的预后有关。
{"title":"A novel PIK3CA hot-spot mutation in breast cancer patients detected by HRM-COLD-PCR analysis.","authors":"Saoussen Debouki-Joudi, Wala Ben Kridis, Fatma Trifa, Wajdi Ayadi, Abdelmajid Khabir, Tahia Sellami-Boudawara, Jamel Daoud, Afef Khanfir, Raja Mokdad-Gargouri","doi":"10.3233/BD-240005","DOIUrl":"10.3233/BD-240005","url":null,"abstract":"<p><strong>Background: </strong>The PI3K protein is involved in the PI3K/AKT/mTOR pathway. Deregulation of this pathway through PIK3CA mutation is common in various tumors. The aim of this work is to identify hotspot mutation at exons 9 and 20 in Tunisian patients with sporadic or hereditary breast cancer.</p><p><strong>Methods: </strong>Hotspot mutations in exon 9 and exon 20 of the PIK3CA gene were identified by QPCR-High Resolution Melting followed by COLD-PCR and sequencing in 63 (42 sporadic cases and 21 hereditary cases) tumor tissues collected from Tunisian patient with breast cancer. MCF7, and BT20 breast cancer cell lines harboring the PIK3CA hotspot mutations E545K and H1047R in exon 9 and exon 20 respectively, were used as controls in HRM experiments.</p><p><strong>Results: </strong>PIK3CA hotspot mutations were detected in 66.7% (28 out of 42) of sporadic BC cases, and in 14.3% (3 out of 21) of hereditary BC. The E545K and the H1048Y were the most prevalent mutations identified in patients with sporadic and hereditary BC, whereas the H1047R hotspot mutation was not found in our patients. Statistical analysis showed that PIK3CA mutation associated with an aggressive behavior in patients with sporadic BC, while it's correlated with age, tumor stage and tumor size in the group patients with hereditary breast cancer.</p><p><strong>Conclusions: </strong>Our results showed a novel PIK3CA hotspot mutation in Tunisian breast cancer patients detected by HRM-COLD-PCR. Moreover, the absence of PIK3CA hotspot mutation associated with good prognosis.</p>","PeriodicalId":9224,"journal":{"name":"Breast disease","volume":"43 1","pages":"213-221"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11307001/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141466234","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
PD-1/PD-L1 pathway: Current research in breast cancer. PD-1/PD-L1 通路:乳腺癌研究现状
Pub Date : 2024-01-01 DOI: 10.3233/BD-249006
Salman Ardi Syamsu, Muhammad Faruk, Nilam Smaradania, Elridho Sampepajung, Agung Sindu Pranoto, Febie Irsandy, Iin Fadhilah Utami Tammasse

Introduction: Immunotherapy has shown encouraging outcomes in breast cancer (BC) treatment in recent years. The programmed cell death ligand 1 (PD-L1) transmembrane protein is suggested to function as a co-inhibitory factor in the immune response, where it collaborates with programmed cell death protein 1 (PD-1) to stimulate apoptosis, suppress cytokine release from PD-1 positive cells, and limit the growth of PD-1 positive cells. Furthermore, in many malignancies, PD-L1 reduces the immune system's response to neoplastic cells. These observations suggest that the PD-1/PD-L1 axis plays a vital role in cancer therapy and the regulation of cancer immune escape mechanisms. This review aimed to provide an overview of the functions of PD-1 and PD-L1 in BC cancer therapy.

Methods: This research design is a literature review. The style is a traditional review on topics or variables relating to the PD-1/PD-L1 pathway. A literature search was carried out using three online databases.

Results: The search using the keywords yielded a total of 248 studies. Each result was filtered again according to the inclusion and exclusion criteria, resulting in a final total of 4 studies to be included in the literature review.

Conclusions: The combination of PD-1/PD-L1 is essential for many malignancies. According to the evidence presented, this combination presents both an opportunity and a challenge in cancer treatment. Since many solid cancers, especially BC, express high levels of PD-1/PD-L1, cancer treatment mainly involves targeted therapies.

简介近年来,免疫疗法在乳腺癌(BC)治疗中取得了令人鼓舞的成果。程序性细胞死亡配体 1(PD-L1)跨膜蛋白被认为是免疫反应中的共同抑制因子,它与程序性细胞死亡蛋白 1(PD-1)合作刺激细胞凋亡,抑制 PD-1 阳性细胞释放细胞因子,并限制 PD-1 阳性细胞的生长。此外,在许多恶性肿瘤中,PD-L1 会降低免疫系统对肿瘤细胞的反应。这些观察结果表明,PD-1/PD-L1 轴在癌症治疗和癌症免疫逃逸机制调控中发挥着重要作用。本综述旨在概述 PD-1 和 PD-L1 在 BC 癌症治疗中的功能:本研究设计为文献综述。文体为传统综述,涉及与 PD-1/PD-L1 通路相关的主题或变量。使用三个在线数据库进行了文献检索:结果:使用关键词进行检索共获得 248 项研究。根据纳入和排除标准对每项结果再次进行筛选,最终共有 4 项研究被纳入文献综述:结论:PD-1/PD-L1联合疗法对许多恶性肿瘤都至关重要。结论:PD-1/PD-L1 组合对于许多恶性肿瘤来说都是必不可少的,根据所提供的证据,这种组合在癌症治疗中既是机遇也是挑战。由于许多实体瘤(尤其是 BC)表达高水平的 PD-1/PD-L1,因此癌症治疗主要涉及靶向疗法。
{"title":"PD-1/PD-L1 pathway: Current research in breast cancer.","authors":"Salman Ardi Syamsu, Muhammad Faruk, Nilam Smaradania, Elridho Sampepajung, Agung Sindu Pranoto, Febie Irsandy, Iin Fadhilah Utami Tammasse","doi":"10.3233/BD-249006","DOIUrl":"10.3233/BD-249006","url":null,"abstract":"<p><strong>Introduction: </strong>Immunotherapy has shown encouraging outcomes in breast cancer (BC) treatment in recent years. The programmed cell death ligand 1 (PD-L1) transmembrane protein is suggested to function as a co-inhibitory factor in the immune response, where it collaborates with programmed cell death protein 1 (PD-1) to stimulate apoptosis, suppress cytokine release from PD-1 positive cells, and limit the growth of PD-1 positive cells. Furthermore, in many malignancies, PD-L1 reduces the immune system's response to neoplastic cells. These observations suggest that the PD-1/PD-L1 axis plays a vital role in cancer therapy and the regulation of cancer immune escape mechanisms. This review aimed to provide an overview of the functions of PD-1 and PD-L1 in BC cancer therapy.</p><p><strong>Methods: </strong>This research design is a literature review. The style is a traditional review on topics or variables relating to the PD-1/PD-L1 pathway. A literature search was carried out using three online databases.</p><p><strong>Results: </strong>The search using the keywords yielded a total of 248 studies. Each result was filtered again according to the inclusion and exclusion criteria, resulting in a final total of 4 studies to be included in the literature review.</p><p><strong>Conclusions: </strong>The combination of PD-1/PD-L1 is essential for many malignancies. According to the evidence presented, this combination presents both an opportunity and a challenge in cancer treatment. Since many solid cancers, especially BC, express high levels of PD-1/PD-L1, cancer treatment mainly involves targeted therapies.</p>","PeriodicalId":9224,"journal":{"name":"Breast disease","volume":"43 1","pages":"79-92"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11091639/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140859751","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The relationship of changes in molecular subtypes with metastases and progression-free survival in breast cancer. 乳腺癌分子亚型的变化与转移和无进展生存期的关系。
Pub Date : 2024-01-01 DOI: 10.3233/BD-249000
Fitran Amansyah, Prihantono Prihantono, Firdaus Hamid, Salman Ardi Syamsu, John Pieter, Muhammad Faruk

Background: Molecular subtyping of breast cancer cells is increasingly being developed as an initial step in selecting therapy and predicting the prognosis of breast cancer patients. During breast cancer, the molecular subtype of cancer cells can change. This study aimed to analyze the relationship between changes in the intrinsic subtype of breast cancer with metastasis and progression-free survival in breast cancer patients.

Methods: This was a retrospective cohort study of patients diagnosed with breast cancer from 2016 to 2021. The molecular subtypes from the immunohistochemical examination results were recorded twice, and metastasis and progression-free survival (PFS) were recorded. The data were analyzed using the chi-square test and SPSS 26.

Results: Of the 44 patients, 19 (43.2%) experienced a change in molecular subtype, and 25 (56.8%) did not. No significant relationship existed between changes in molecular subtype and metastasis (p = 0.405). No significant relationship existed between changes in molecular subtype and PFS (p = 0.900). A significant relationship was found between changes in the molecular subtype and PFS in the patients with changes in the molecular subtype (p = 0.022).

Conclusions: Changes in the intrinsic subtype were associated with PFS in breast cancer patients. Patients with an intrinsic subtype that changed to triple-negative showed worse PFS.

背景:乳腺癌细胞的分子亚型越来越多地被开发出来,作为选择治疗方法和预测乳腺癌患者预后的第一步。在乳腺癌发病过程中,癌细胞的分子亚型会发生变化。本研究旨在分析乳腺癌内在亚型的变化与乳腺癌患者转移和无进展生存期之间的关系:这是一项回顾性队列研究,研究对象为2016年至2021年确诊的乳腺癌患者。两次记录免疫组化检查结果中的分子亚型,并记录转移和无进展生存期(PFS)。数据采用卡方检验和 SPSS 26 进行分析:结果:在 44 例患者中,19 例(43.2%)的分子亚型发生了变化,25 例(56.8%)没有发生变化。分子亚型变化与转移之间无明显关系(P = 0.405)。分子亚型变化与 PFS 之间无明显关系(p = 0.900)。在分子亚型发生变化的患者中,分子亚型的变化与 PFS 之间存在明显关系(p = 0.022):结论:内在亚型的变化与乳腺癌患者的生存期有关。结论:固有亚型的变化与乳腺癌患者的生存期有关,固有亚型变为三阴性的患者生存期更短。
{"title":"The relationship of changes in molecular subtypes with metastases and progression-free survival in breast cancer.","authors":"Fitran Amansyah, Prihantono Prihantono, Firdaus Hamid, Salman Ardi Syamsu, John Pieter, Muhammad Faruk","doi":"10.3233/BD-249000","DOIUrl":"10.3233/BD-249000","url":null,"abstract":"<p><strong>Background: </strong>Molecular subtyping of breast cancer cells is increasingly being developed as an initial step in selecting therapy and predicting the prognosis of breast cancer patients. During breast cancer, the molecular subtype of cancer cells can change. This study aimed to analyze the relationship between changes in the intrinsic subtype of breast cancer with metastasis and progression-free survival in breast cancer patients.</p><p><strong>Methods: </strong>This was a retrospective cohort study of patients diagnosed with breast cancer from 2016 to 2021. The molecular subtypes from the immunohistochemical examination results were recorded twice, and metastasis and progression-free survival (PFS) were recorded. The data were analyzed using the chi-square test and SPSS 26.</p><p><strong>Results: </strong>Of the 44 patients, 19 (43.2%) experienced a change in molecular subtype, and 25 (56.8%) did not. No significant relationship existed between changes in molecular subtype and metastasis (p = 0.405). No significant relationship existed between changes in molecular subtype and PFS (p = 0.900). A significant relationship was found between changes in the molecular subtype and PFS in the patients with changes in the molecular subtype (p = 0.022).</p><p><strong>Conclusions: </strong>Changes in the intrinsic subtype were associated with PFS in breast cancer patients. Patients with an intrinsic subtype that changed to triple-negative showed worse PFS.</p>","PeriodicalId":9224,"journal":{"name":"Breast disease","volume":"43 1","pages":"71-78"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11091556/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140853925","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Nipple-sparing mastectomy and immediate breast reconstruction by prepectoral implant for the management of giant phyllodes tumors: A case series. 巨型植物瘤的保乳乳房切除术和胸前假体即刻乳房重建术:病例系列。
Pub Date : 2024-01-01 DOI: 10.3233/BD-240011
Khaled M Abdelwahab, Sara Elsaeed, Omar Hamdy, Mahmoud M Saleh, Amr Hosam

Phyllodes tumor is an uncommon breast neoplasm that is present in variable sizes. Giant phyllodes are those larger than 10 cm in diameter. Clinically, giant phyllodes tumors present as a visible, rapidly growing mass distorting the breast contour. Such tumors with large size and rapid growth rate suggest a phyllode diagnosis of fibroadenoma. Planning a standard treatment strategy for these tumors is quite challenging. While adequate surgical excision with tumor-free resection margins is the standard of care for most giant phyllodes cases, borderline and malignant giant phyllodes tumors might require wider resections given their high recurrence rates. Some authors described total mastectomy as the treatment option for giant borderline and malignant phyllodes to obtain wide, clear margins. Between March 2022 and September 2023, our surgical oncology department presented and operated on three cases of giant phyllodes. They underwent a nipple-sparing mastectomy and immediate breast reconstruction using pre-pectoral silicone implants. We think that with such a procedure, we can benefit from the wide, safe margins of mastectomy that have been proven to decrease local recurrence rates while considering the aesthetic outcome.

叶状瘤是一种不常见的乳腺肿瘤,大小不一。巨型植物瘤是指直径大于 10 厘米的肿瘤。临床上,巨型植物瘤表现为明显的、快速生长的肿块,使乳房轮廓变形。此类肿瘤体积大、生长速度快,应诊断为纤维腺瘤。为这类肿瘤制定标准的治疗策略相当具有挑战性。对大多数巨型乳腺纤维瘤病例来说,无肿瘤切除边缘的充分手术切除是标准治疗方法,但鉴于其复发率高,边缘性和恶性巨型乳腺纤维瘤可能需要更广泛的切除。一些作者指出,全乳房切除术是治疗边缘性和恶性巨大蝶形花瘤的选择,以获得宽而清晰的边缘。2022 年 3 月至 2023 年 9 月期间,我院肿瘤外科接诊并手术治疗了三例巨大蝶形瘤患者。她们接受了乳头保留乳房切除术,并立即使用胸大肌前硅胶假体进行乳房重建。我们认为,通过这种手术,我们可以从乳房切除术的广泛、安全切缘中获益,这种切缘已被证明可以降低局部复发率,同时兼顾美学效果。
{"title":"Nipple-sparing mastectomy and immediate breast reconstruction by prepectoral implant for the management of giant phyllodes tumors: A case series.","authors":"Khaled M Abdelwahab, Sara Elsaeed, Omar Hamdy, Mahmoud M Saleh, Amr Hosam","doi":"10.3233/BD-240011","DOIUrl":"10.3233/BD-240011","url":null,"abstract":"<p><p>Phyllodes tumor is an uncommon breast neoplasm that is present in variable sizes. Giant phyllodes are those larger than 10 cm in diameter. Clinically, giant phyllodes tumors present as a visible, rapidly growing mass distorting the breast contour. Such tumors with large size and rapid growth rate suggest a phyllode diagnosis of fibroadenoma. Planning a standard treatment strategy for these tumors is quite challenging. While adequate surgical excision with tumor-free resection margins is the standard of care for most giant phyllodes cases, borderline and malignant giant phyllodes tumors might require wider resections given their high recurrence rates. Some authors described total mastectomy as the treatment option for giant borderline and malignant phyllodes to obtain wide, clear margins. Between March 2022 and September 2023, our surgical oncology department presented and operated on three cases of giant phyllodes. They underwent a nipple-sparing mastectomy and immediate breast reconstruction using pre-pectoral silicone implants. We think that with such a procedure, we can benefit from the wide, safe margins of mastectomy that have been proven to decrease local recurrence rates while considering the aesthetic outcome.</p>","PeriodicalId":9224,"journal":{"name":"Breast disease","volume":"43 1","pages":"231-236"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11307034/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141537628","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The quality of life assessment of breast cancer patients. 乳腺癌患者的生活质量评估。
Pub Date : 2024-01-01 DOI: 10.3233/BD-249008
Uswatun Hasanah, Mardiana Ahmad, Prihantono Prihantono, Andi Nilawati Usman, Aryadi Arsyad, Dinah Inrawati Agustin

Objectives: Research investigating the quality of life (QOL) of breast cancer patients undergoing chemotherapy has yielded useful knowledge regarding the effects of cancer treatment on the quality of life of patients. This study reviews the assessment of the quality of life for those diagnosed with breast cancer.

Design: A systematic review was conducted.

Data sources: This systematic review utilized online databases, including PubMed, Web of Science, Scopus, and Google Scholar. A search ranging from 2018 to 2024 was carried out.

Review method: Medical Subject Headings (MESH) were used for keyword selection along with other target keywords, such as "Quality of life", "Breast cancer", "Chemotherapy", "Treatment side effects", "Patient experience", "Psychosocial well-being", "Physical functioning", "Emotional distress", and "Supportive care". We reviewed and included all English-language publications. A narrative synthesis was conducted to present the results of the studies.

Results: A total of 300 studies were obtained from the search using the specified keywords. Each result underwent another filtering round after applying the inclusion and exclusion criteria. This process led to a final selection of 20 papers that met the requirements and were included in the systematic review.

Conclusion: The use of instruments to measure the quality of life (QoL) of breast cancer patients is crucial in understanding the impact of breast cancer on patients' lives, from physical and mental health to social aspects.

研究目的对接受化疗的乳腺癌患者的生活质量(QOL)进行调查的研究,为了解癌症治疗对患者生活质量的影响提供了有用的知识。本研究回顾了对乳腺癌患者生活质量的评估:设计:进行了系统性回顾:本系统综述利用了在线数据库,包括 PubMed、Web of Science、Scopus 和 Google Scholar。检索时间为 2018 年至 2024 年:在选择关键词时使用了医学主题词表(MESH)以及其他目标关键词,如 "生活质量"、"乳腺癌"、"化疗"、"治疗副作用"、"患者体验"、"社会心理健康"、"身体机能"、"情绪困扰 "和 "支持性护理"。我们审查并收录了所有英文出版物。我们对研究结果进行了叙述性综合:使用指定关键词进行搜索,共获得 300 项研究结果。在应用纳入和排除标准后,每项结果都经过了另一轮筛选。通过这一过程,最终筛选出 20 篇符合要求的论文,并将其纳入系统综述:使用工具测量乳腺癌患者的生活质量(QoL)对于了解乳腺癌对患者生活的影响(从身体和心理健康到社会方面)至关重要。
{"title":"The quality of life assessment of breast cancer patients.","authors":"Uswatun Hasanah, Mardiana Ahmad, Prihantono Prihantono, Andi Nilawati Usman, Aryadi Arsyad, Dinah Inrawati Agustin","doi":"10.3233/BD-249008","DOIUrl":"10.3233/BD-249008","url":null,"abstract":"<p><strong>Objectives: </strong>Research investigating the quality of life (QOL) of breast cancer patients undergoing chemotherapy has yielded useful knowledge regarding the effects of cancer treatment on the quality of life of patients. This study reviews the assessment of the quality of life for those diagnosed with breast cancer.</p><p><strong>Design: </strong>A systematic review was conducted.</p><p><strong>Data sources: </strong>This systematic review utilized online databases, including PubMed, Web of Science, Scopus, and Google Scholar. A search ranging from 2018 to 2024 was carried out.</p><p><strong>Review method: </strong>Medical Subject Headings (MESH) were used for keyword selection along with other target keywords, such as \"Quality of life\", \"Breast cancer\", \"Chemotherapy\", \"Treatment side effects\", \"Patient experience\", \"Psychosocial well-being\", \"Physical functioning\", \"Emotional distress\", and \"Supportive care\". We reviewed and included all English-language publications. A narrative synthesis was conducted to present the results of the studies.</p><p><strong>Results: </strong>A total of 300 studies were obtained from the search using the specified keywords. Each result underwent another filtering round after applying the inclusion and exclusion criteria. This process led to a final selection of 20 papers that met the requirements and were included in the systematic review.</p><p><strong>Conclusion: </strong>The use of instruments to measure the quality of life (QoL) of breast cancer patients is crucial in understanding the impact of breast cancer on patients' lives, from physical and mental health to social aspects.</p>","PeriodicalId":9224,"journal":{"name":"Breast disease","volume":"43 1","pages":"173-185"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11191531/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141320561","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
In-silico prediction of anti-breast cancer activity of ginger (Zingiber officinale) using machine learning techniques. 利用机器学习技术对生姜(Zingiber officinale)的抗乳腺癌活性进行室内预测。
Pub Date : 2024-01-01 DOI: 10.3233/BD-249002
Marisca Evalina Gondokesumo, Muhammad Rezki Rasyak

Introduction: Indonesian civilization extensively uses traditional medicine to cure illnesses and preserve health. The lack of knowledge on the security and efficacy of medicinal plants is still a significant concern. Although the precise chemicals responsible for this impact are unknown, ginger is a common medicinal plant in Southeast Asia that may have anticancer qualities.

Method: Using data from Dudedocking, a machine-learning model was created to predict possible breast anticancer chemicals from ginger. The model was used to forecast substances that block KIT and MAPK2 proteins, essential elements in breast cancer.

Result: Beta-carotene, 5-Hydroxy-74'-dimethoxyflavone, [12]-Shogaol, Isogingerenone B, curcumin, Trans-[10]-Shogaol, Gingerenone A, Dihydrocurcumin, and demethoxycurcumin were all superior to the reference ligand for MAPK2, according to molecular docking studies. Lycopene, [8]-Shogaol, [6]-Shogaol, and [1]-Paradol exhibited low toxicity and no Lipinski violations, but beta carotene had toxic predictions and Lipinski violations. It was anticipated that all three substances would have anticarcinogenic qualities.

Conclusion: Overall, this study shows the value of machine learning in drug development and offers insightful information on possible anticancer chemicals from ginger.

简介印度尼西亚文明广泛使用传统医药来治疗疾病和保护健康。但人们对药用植物的安全性和功效缺乏了解,这仍是一个重大问题。虽然造成这种影响的确切化学物质尚不清楚,但生姜是东南亚常见的药用植物,可能具有抗癌功效:方法:利用来自 Dudedocking 的数据,创建了一个机器学习模型来预测生姜中可能存在的乳腺癌抗癌化学物质。该模型用于预测可阻断 KIT 和 MAPK2 蛋白的物质,而 KIT 和 MAPK2 蛋白是乳腺癌的基本要素:结果:根据分子对接研究,β-胡萝卜素、5-羟基-74'-二甲氧基黄酮、[12]-肖高醇、异姜黄酮 B、姜黄素、反式-[10]-肖高醇、姜黄酮 A、二氢姜黄素和去甲氧基姜黄素都优于 MAPK2 的参考配体。番茄红素、[8]-Shogaol、[6]-Shogaol 和 [1]-Paradol 显示出低毒性,没有违反 Lipinski 规定的情况,但 beta 胡萝卜素有毒性预测和违反 Lipinski 规定的情况。预计这三种物质都具有抗致癌性:总之,这项研究显示了机器学习在药物开发中的价值,并为生姜中可能存在的抗癌化学物质提供了具有洞察力的信息。
{"title":"In-silico prediction of anti-breast cancer activity of ginger (Zingiber officinale) using machine learning techniques.","authors":"Marisca Evalina Gondokesumo, Muhammad Rezki Rasyak","doi":"10.3233/BD-249002","DOIUrl":"10.3233/BD-249002","url":null,"abstract":"<p><strong>Introduction: </strong>Indonesian civilization extensively uses traditional medicine to cure illnesses and preserve health. The lack of knowledge on the security and efficacy of medicinal plants is still a significant concern. Although the precise chemicals responsible for this impact are unknown, ginger is a common medicinal plant in Southeast Asia that may have anticancer qualities.</p><p><strong>Method: </strong>Using data from Dudedocking, a machine-learning model was created to predict possible breast anticancer chemicals from ginger. The model was used to forecast substances that block KIT and MAPK2 proteins, essential elements in breast cancer.</p><p><strong>Result: </strong>Beta-carotene, 5-Hydroxy-74'-dimethoxyflavone, [12]-Shogaol, Isogingerenone B, curcumin, Trans-[10]-Shogaol, Gingerenone A, Dihydrocurcumin, and demethoxycurcumin were all superior to the reference ligand for MAPK2, according to molecular docking studies. Lycopene, [8]-Shogaol, [6]-Shogaol, and [1]-Paradol exhibited low toxicity and no Lipinski violations, but beta carotene had toxic predictions and Lipinski violations. It was anticipated that all three substances would have anticarcinogenic qualities.</p><p><strong>Conclusion: </strong>Overall, this study shows the value of machine learning in drug development and offers insightful information on possible anticancer chemicals from ginger.</p>","PeriodicalId":9224,"journal":{"name":"Breast disease","volume":"43 1","pages":"99-110"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11191463/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140956228","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Erratum to: Anti-IL-8 monoclonal antibodies inhibits the autophagic activity and cancer stem cells maintenance within breast cancer tumor microenvironment. 勘误:抗IL-8单克隆抗体抑制乳腺癌肿瘤微环境中的自噬活性和癌症干细胞的维持。
Pub Date : 2024-01-01 DOI: 10.3233/BD-241111
Seham Abou Shousha, Eman M Osman, Suzan Baheeg, Yasmine Shahine
{"title":"Erratum to: Anti-IL-8 monoclonal antibodies inhibits the autophagic activity and cancer stem cells maintenance within breast cancer tumor microenvironment.","authors":"Seham Abou Shousha, Eman M Osman, Suzan Baheeg, Yasmine Shahine","doi":"10.3233/BD-241111","DOIUrl":"10.3233/BD-241111","url":null,"abstract":"","PeriodicalId":9224,"journal":{"name":"Breast disease","volume":"43 1","pages":"157"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11301638/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141183624","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Influence of variables on breast self-examination: Potential barrier or enhancement of breast cancer prevention. 各种变量对乳房自我检查的影响:预防乳腺癌的潜在障碍或促进因素。
Pub Date : 2024-01-01 DOI: 10.3233/BD-249001
Hijrah Hijrah, Andi Nilawati Usman, Yusring Sanusi Baso, Syafruddin Syarif, Mardiana Ahmad, Zafitri Nulandari

Introduction: Breast self-examination (BSE) is an important tool for early detection of breast cancer and can contribute to increased awareness and familiarity with breast tissue. This study aimed to review factors that influenced BSE in preventing breast cancer.

Methods: In the initial stage of searching for journal articles, 186 journals were obtained, then screening was carried out within a time span of 2019-2024 and using Indonesian and English 54 journals. Of the 12 journals reviewed, the results showed that 4 journals reviewed had conducted pre and post-BSE practices, and 8 journal reviews conducted BSE practices conducted by students and health workers.

Results: Several factors play an important role in implementing BSE, namely age, knowledge, history of exposure to information, family history, ethnicity, and attitude. Overall, the study shows that the need to create awareness and educate women, especially rural women, on the importance of BSE as a preventive measure for breast cancer is paramount.

Conclusions: Factors influencing the implementation of BSE can be a barrier or an enhancement in breast cancer prevention.

简介乳房自我检查(BSE)是早期发现乳腺癌的重要工具,有助于提高人们对乳房组织的认识和熟悉程度。本研究旨在探讨影响 BSE 预防乳腺癌的因素:在搜索期刊论文的初始阶段,获得了 186 种期刊,然后在 2019-2024 年的时间跨度内,使用印尼语和英语对 54 种期刊进行了筛选。结果显示,在12篇期刊中,有4篇期刊进行了BSE前后的实践,8篇期刊进行了学生和卫生工作者的BSE实践:有几个因素对实施 BSE 起着重要作用,即年龄、知识、信息接触史、家族史、种族和态度。总之,研究表明,最重要的是要让妇女,尤其是农村妇女认识到 BSE 作为乳腺癌预防措施的重要性:结论:影响 BSE 实施的因素可能会阻碍乳腺癌的预防,也可能会促进乳腺癌的预防。
{"title":"Influence of variables on breast self-examination: Potential barrier or enhancement of breast cancer prevention.","authors":"Hijrah Hijrah, Andi Nilawati Usman, Yusring Sanusi Baso, Syafruddin Syarif, Mardiana Ahmad, Zafitri Nulandari","doi":"10.3233/BD-249001","DOIUrl":"10.3233/BD-249001","url":null,"abstract":"<p><strong>Introduction: </strong>Breast self-examination (BSE) is an important tool for early detection of breast cancer and can contribute to increased awareness and familiarity with breast tissue. This study aimed to review factors that influenced BSE in preventing breast cancer.</p><p><strong>Methods: </strong>In the initial stage of searching for journal articles, 186 journals were obtained, then screening was carried out within a time span of 2019-2024 and using Indonesian and English 54 journals. Of the 12 journals reviewed, the results showed that 4 journals reviewed had conducted pre and post-BSE practices, and 8 journal reviews conducted BSE practices conducted by students and health workers.</p><p><strong>Results: </strong>Several factors play an important role in implementing BSE, namely age, knowledge, history of exposure to information, family history, ethnicity, and attitude. Overall, the study shows that the need to create awareness and educate women, especially rural women, on the importance of BSE as a preventive measure for breast cancer is paramount.</p><p><strong>Conclusions: </strong>Factors influencing the implementation of BSE can be a barrier or an enhancement in breast cancer prevention.</p>","PeriodicalId":9224,"journal":{"name":"Breast disease","volume":"43 1","pages":"145-155"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11191488/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141183634","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Breast gel based on Boswellia serrata, Betaine and myo-Inositol improves cyclic mastodynia in fertile women: A retrospective clinical study. 基于乳香、甜菜碱和肌醇的乳房凝胶可改善育龄妇女的周期性乳房疼痛:回顾性临床研究
Pub Date : 2024-01-01 DOI: 10.3233/BD-240012
Moira Burratti, Giuseppina Morano, Chiara Pasquale, Grazia Di Fonso, Loredana Costabile

Background: The management of mastodynia plays a central role in improving women quality of life. Despite its high occurrence, specific therapeutic guidelines for mastalgia are still lacking. Available therapies include unspecific anti-inflammatories, even though they may often expose to undesirable effects and low compliance.

Objective: The aim of this study was to highlight the efficacy of the topical application of combined natural molecules including Boswellia serrata, Betaine and myo-Inositol in improving cyclic mastalgia.

Methods: In this retrospective pilot clinical study, patients with cyclic mastalgia applied a specific breast gel for three months. The severity of the pain was measured through the Visual Analogue Score (VAS) in the treated group compared to untreated one. Treated patients also filled in a questionnaire evaluating acceptance and safety of the breast gel.

Results: This pilot clinical study demonstrated for the first time the efficacy of the topical application of a breast gel based on Betaine, Boswellia serrata, and myo-Inositol in improving cyclic mastodynia. The completed questionnaires also revealed high levels of acceptance, as both safety and compliance.

Conclusions: Besides confirming the positive effects of these natural molecules in the management of conditions affecting breast physiology - so far evaluated as oral supplementation - the obtained results pave the way for further studies supporting the use of such molecules as a tailored medical device in the management of breast pain, thus also opening toward a combined oral and topical approach.

背景:乳房疼痛的治疗在提高妇女生活质量方面发挥着重要作用。尽管乳房疼痛的发生率很高,但目前仍缺乏针对乳房疼痛的具体治疗指南。现有的疗法包括非特异性消炎药,尽管这些药物可能经常会产生不良影响,而且依从性较低:本研究旨在强调乳香、甜菜碱和肌醇等多种天然分子的局部应用对改善周期性乳痛症的疗效:在这项回顾性试点临床研究中,周期性乳房疼痛患者使用了一种特定的乳房凝胶,为期三个月。通过视觉模拟评分(VAS)测量治疗组与未治疗组的疼痛严重程度。接受治疗的患者还填写了一份问卷,对乳房凝胶的接受度和安全性进行评估:这项试验性临床研究首次证明了局部使用以甜菜碱、乳香和肌醇为基础的乳房凝胶对改善周期性乳房疼痛的疗效。完成的调查问卷还显示,该产品在安全性和依从性方面都获得了高度认可:结论:除了证实这些天然分子在治疗影响乳房生理机能的病症方面具有积极作用(迄今为止,这些天然分子都是以口服补充剂的形式进行评估的),所获得的结果还为进一步的研究铺平了道路,这些研究支持将这些分子用作治疗乳房疼痛的定制医疗设备,从而也为口服和外用相结合的方法开辟了道路。
{"title":"Breast gel based on Boswellia serrata, Betaine and myo-Inositol improves cyclic mastodynia in fertile women: A retrospective clinical study.","authors":"Moira Burratti, Giuseppina Morano, Chiara Pasquale, Grazia Di Fonso, Loredana Costabile","doi":"10.3233/BD-240012","DOIUrl":"10.3233/BD-240012","url":null,"abstract":"<p><strong>Background: </strong>The management of mastodynia plays a central role in improving women quality of life. Despite its high occurrence, specific therapeutic guidelines for mastalgia are still lacking. Available therapies include unspecific anti-inflammatories, even though they may often expose to undesirable effects and low compliance.</p><p><strong>Objective: </strong>The aim of this study was to highlight the efficacy of the topical application of combined natural molecules including Boswellia serrata, Betaine and myo-Inositol in improving cyclic mastalgia.</p><p><strong>Methods: </strong>In this retrospective pilot clinical study, patients with cyclic mastalgia applied a specific breast gel for three months. The severity of the pain was measured through the Visual Analogue Score (VAS) in the treated group compared to untreated one. Treated patients also filled in a questionnaire evaluating acceptance and safety of the breast gel.</p><p><strong>Results: </strong>This pilot clinical study demonstrated for the first time the efficacy of the topical application of a breast gel based on Betaine, Boswellia serrata, and myo-Inositol in improving cyclic mastodynia. The completed questionnaires also revealed high levels of acceptance, as both safety and compliance.</p><p><strong>Conclusions: </strong>Besides confirming the positive effects of these natural molecules in the management of conditions affecting breast physiology - so far evaluated as oral supplementation - the obtained results pave the way for further studies supporting the use of such molecules as a tailored medical device in the management of breast pain, thus also opening toward a combined oral and topical approach.</p>","PeriodicalId":9224,"journal":{"name":"Breast disease","volume":"43 1","pages":"243-249"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11380272/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142104475","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Breast disease
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1